Knowledge Library

Development of Rodent Models for Diabetic Neuropathy

Diabetic neuropathy, a common complication of diabetes, affects approximately 50% of diabetic patients and can lead to a range of symptoms, including chronic pain, numbness, and loss of sensation in the extremities, particularly the feet. Animal models are crucial for understanding the mechanisms of diabetic neuropathy and developing novel treatments. However, reproducing the complexity of …Read More >

Resource Type: Latest Science, Poster
Resource Topic: in vivo Pharmacology, Metabolic Diseases

VIEW

STZ-Induced Diabetic Retinopathy Models

Diabetic retinopathy is a major contributor to vision loss and blindness in working-age adults with diabetes. Developing animal models that accurately represent human diabetic retinopathy is challenging because this disease is complex and involves multiple factors, including genetic predisposition, duration of diabetes, and glycemic control. It is crucial to replicate the human pathophysiology in these …Read More >

Resource Type: Latest Science, Poster
Resource Topic: in vivo Pharmacology, Metabolic Diseases

VIEW

Overcoming PARP Inhibitor Resistance in an Olaparib-Induced Model

Poly (ADP-ribose) polymerase inhibitors (PARPi) have emerged as a promising therapeutic approach in the treatment of various cancers, particularly those with deficiencies in DNA repair mechanisms. However, the clinical efficacy of PARPi is often limited by the development of resistance, which poses a significant challenge to their long-term use. Elucidating the molecular mechanisms underlying PARPi …Read More >

Resource Type: Latest Science, Poster
Resource Topic: in vivo Pharmacology, Oncology

VIEW

Effects of Incretin-Based Therapies on Metabolic and Muscular Homeostasis

Advances in understanding how the body regulates metabolism, particularly the role of incretin hormones, have directly led to the development of effective therapies for improving glycemic control and managing weight, particularly for individuals with type 2 diabetes and/or obesity. These medications, such as GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists, mimic or enhance the …Read More >

Resource Type: Latest Science, Poster
Resource Topic: in vivo Pharmacology, Metabolic Diseases

VIEW

Targeting MC4R with Setmelanotide Improves Metabolic Parameters in DIO Mice

The global obesity epidemic is a significant public health concern, increasing the risk of various chronic diseases, including diabetes, cardiovascular diseases, and certain cancers, ultimately reducing overall quality of life. Approximately 1-5% of severely obese patients have been found to carry heterozygous mutations in the melanocortin-4 receptor (MC4R) gene. Targeting MC4R, which regulates appetite and …Read More >

Resource Type: Latest Science, Poster
Resource Topic: in vivo Pharmacology, Metabolic Diseases

VIEW

Targeting the CB1 Receptor for Enhanced Obesity Management

Obesity is a significant risk factor for developing conditions like type 2 diabetes, heart disease, stroke, and several types of cancer.  The cannabinoid-1 (CB1) receptor plays a significant role in regulating energy homeostasis, including appetite, food intake, and metabolism, and this receptor is emerging as a promising target for the treatment of obesity.  Although rimonabant, …Read More >

Resource Type: Latest Science, Poster
Resource Topic: in vivo Pharmacology, Metabolic Diseases

VIEW

OncoWuXi Express: Animal Models of Parkinson’s Disease

Introduction: OncoWuXi Express will continue to keep you informed about updates to our online pharmacology model database (OncoWuXi Database), as well as our recent progress in preclinical research. In this issue, we showcase animal models related to Parkinson’s disease. https://onco.wuxiapptec.com Introduction Pathogenesis of Parkinson’s Disease Parkinson’s Disease (PD) is a widely prevalent neurodegenerative disorder globally. …Read More >

Resource Type: Article, Blog
Resource Topic: Central Nervous System & Pain, in vivo Pharmacology

VIEW

Innovative R&D Strategies for Peptide Drugs in Obesity Treatment

Introduction: Obesity has emerged as a pressing global public health issue, with its prevalence escalating at an unprecedented rate across the world. Body Mass Index (BMI) is a commonly used indicator to assess the degree of obesity. According to the World Obesity Atlas 2025, by 2030, over 2.9 billion adults globally will have a high …Read More >

Resource Type: Article, Blog
Resource Topic: in vivo Pharmacology, Metabolic Diseases, Peptides

VIEW

Systemic Lupus Erythematosus Animal Models

Systemic lupus erythematosus (SLE) is a serious, chronic autoimmune disorder characterized by a heterogeneous clinical presentation, in which various organs and systems are affected in different ways and with varying degrees of severity.  SLE is characterized by an autoimmune reaction involving the innate and adaptive immune systems, including dendritic cells, T cells, and B cells. …Read More >

Resource Type: Presentation
Resource Topic: in vivo Pharmacology, Rare Diseases

VIEW


Resource Topics
× peptide, amino acid

Contact An Expert Today!